Research News
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
Factors that stress the body, such as obesity, can make people more likely to develop macular degeneration when they’re older, even if they’ve returned to a normal weight, new research shows.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
A potential new amyloid-clearing Alzheimer’s drug has been shown to slow cognitive decline in the early stages of Alzheimer’s disease.
A new BrightFocus-funded study suggests that an FDA-approved sleeping pill may slow or stop the progression of Alzheimer’s disease, promising findings that are sparking further investigation.
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
BrightFocus-funded research offers the potential to restore vision loss due to glaucoma using cell replacement therapy.
Researchers have identified a new gene region in people of African descent that reduces Alzheimer's disease risk—highlighting the importance of diversity and inclusion of all populations in research.
A recent study reveals that an anti-inflammatory drug approved to treat certain autoimmune diseases can counteract a protein in the body that’s linked to age-related macular degeneration. These findings may lead to a new treatment option for the disease.
A BrightFocus Foundation-funded study found that even moderate alcohol use can cause changes in the brain that may accelerate Alzheimer’s disease, shedding new light on a possible modifiable risk factor for dementia.
